PGR and neoplasm: ER(+)/PR(+) tumours represent approximately 50–70% of all BCa cases, and PR loss is associated with resistance to hormonal therapy and increased tumour invasiveness [6], which is corroborated by numerous reports of substantially poorer outcome of patients with ER(+)/PR(−) tumours following tamoxifen-based treatment [7–10].